| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Celia Lin last filed a Form 4 in August 2023, as Chief Medical Officer at VERA. Celia Lin's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 11,010 shares of VERA. The VERA filings lean toward selling, a net 1,490 shares.
Celia Lin has 5 Form 4 filings on record from May 2021 to August 2023, all as Chief Medical Officer at Vera Therapeutics (VERA), 2021–2023.
The 5 reported transactions were 3 option or other derivative awards, 1 open-market sale and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $25K.
The only open-market sale was 1,490 shares of VERA at an average $16.65 on August 21, 2023, about $25K. Twelve months later VERA was up 123%.
Shares as reported in the last Form 4 for each company; the most recent is from August 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.